PortfoliosLab logoPortfoliosLab logo
ISIN
US0906556065
CUSIP
090655408
IPO Date
Jul 27, 2007

Highlights

Market Cap
$7.25M
Enterprise Value
$4.14M
EPS (TTM)
-$0.99
Total Revenue (TTM)
$357.87K
Gross Profit (TTM)
$224.09K
EBITDA (TTM)
-$12.75M
Year Range
$0.16 - $1.89
ROA (TTM)
-238.27%
ROE (TTM)
-365.43%

Share Price Chart


Loading charts...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


BioRestorative Therapies Inc

Often compared with BRTX:
BRTX vs. PIMIX

Performance

BRTX Performance Chart

BioRestorative Therapies Inc (BRTX) is down 65.2% since the beginning of the year. At $0 per share, BRTX is trading 78.4% below its 52-week high of $2. Investors who bought $1,000 worth of BRTX shares 5 years ago would now be looking at an investment worth $14.


Loading charts...

S&P 500 Index

Returns By Period

BioRestorative Therapies Inc (BRTX) has returned -65.19% so far this year and -74.11% over the past 12 months. Over the last ten years, BRTX has returned -64.99% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.


BioRestorative Therapies Inc

1D
-0.15%
1M
96.63%
YTD
-65.19%
6M
-64.74%
1Y
-74.11%
3Y*
-58.49%
5Y*
-57.70%
10Y*
-64.99%

Benchmark (S&P 500 Index)

1D
-0.37%
1M
-0.01%
YTD
9.16%
6M
8.64%
1Y
25.22%
3Y*
19.78%
5Y*
11.99%
10Y*
13.88%
*Multi-year figures are annualized to reflect compound growth (CAGR)

BRTX Monthly Returns History

Based on dividend-adjusted daily data since May 14, 2013, BRTX's average daily return is +0.44%, while the average monthly return is +103.10%. At this rate, an investment would double in approximately 0.1 years.

Historically, 37% of months were positive and 63% were negative. The best month was Aug 2020 with a return of +17,025.0%, while the worst month was Dec 2019 at -88.1%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 9 months.

On a daily basis, BRTX closed higher 35% of trading days. The best single day was Jan 3, 2020 with a return of +404.0%, while the worst single day was Jan 6, 2020 at -59.5%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2026-2.98%-79.96%19.13%-17.27%112.35%-14.44%-65.19%
202566.43%-36.13%17.11%-1.12%-0.28%-5.09%-11.74%25.17%-21.20%6.21%-29.95%8.93%-17.83%
2024-6.32%-14.11%-1.43%2.90%-11.97%62.40%-24.63%7.19%6.10%-10.34%-1.92%-6.54%-17.81%
20236.91%-5.79%22.74%16.47%31.31%-15.19%-34.47%-23.88%-18.64%10.61%-3.03%-9.38%-36.73%
2022-21.89%64.01%-5.94%-19.31%-4.50%-26.80%4.40%6.33%-1.37%0.62%-5.54%-10.42%-36.64%
202152.17%51.43%-24.53%-16.67%-10.00%-33.33%-21.67%-27.66%5.88%-2.64%-57.20%-27.67%-84.28%

Benchmark Metrics

BioRestorative Therapies Inc has an annualized alpha of 194.39%, beta of 0.12, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since May 14, 2013.

  • This stock participated in 251.75% of S&P 500 Index downside but only -67.05% of its upside - more exposed to losses than it benefited from rallies.
  • Beta of 0.12 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
  • R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
194.39%
Beta
0.12
0.00
Upside Capture
-67.05%
Downside Capture
251.75%

Return for Risk

Risk / Return Rank

BRTX ranks 16 for risk / return — in the bottom 16% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.


BRTX Risk / Return Rank: 1616
Overall Rank
BRTX Sharpe Ratio Rank: 1919
Sharpe Ratio Rank
BRTX Sortino Ratio Rank: 2222
Sortino Ratio Rank
BRTX Omega Ratio Rank: 2121
Omega Ratio Rank
BRTX Calmar Ratio Rank: 1111
Calmar Ratio Rank
BRTX Martin Ratio Rank: 1010
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for BioRestorative Therapies Inc (BRTX) and compare them to S&P 500 Index.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


BRTXBenchmarkDifference
Sharpe ratioReturn per unit of total volatility

-2.56

Sortino ratioReturn per unit of downside risk

-3.18

Omega ratioGain probability vs. loss probability

0.94

1.37

-0.43

Calmar ratioReturn relative to maximum drawdown

-0.82

2.78

-3.60

Martin ratioReturn relative to average drawdown

-1.35

12.44

-13.78

Dividends

Dividend History


BioRestorative Therapies Inc doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading charts...

Worst Drawdowns

The table below displays the maximum drawdowns of the BioRestorative Therapies Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the BioRestorative Therapies Inc was 100.00%, occurring on May 20, 2026. The portfolio has not yet recovered.

The current BioRestorative Therapies Inc drawdown is 100.00%.


Related event

Drawdown

Fall

Recovery

Underwater

2026 bear market2026
-100.00%May 2026
12y 11mo
13y 7dJun 2013 - now
2013 correction2013
-17.00%Jun 2013
1d3d
4dJun 2013 - Jun 2013
2013 correction2013
-10.00%May 2013
0s2d
2dMay 2013 - May 2013
2013 pullback2013
-1.00%May 2013
0s7d
7dMay 2013 - May 2013

Drawdown Indicators


BRTXBenchmarkDifference

Max Drawdown

Largest peak-to-trough decline

-100.00%

-56.78%

-43.22%

Max Drawdown (1Y)

Largest decline over 1 year

-90.77%

-9.10%

-81.67%

Max Drawdown (3Y)

Largest decline over 3 years

-97.38%

-18.90%

-78.48%

Max Drawdown (5Y)

Largest decline over 5 years

-99.41%

-25.43%

-73.98%

Max Drawdown (10Y)

Largest decline over 10 years

-100.00%

-33.92%

-66.08%

Current Drawdown

Current decline from peak

-100.00%

-1.80%

-98.20%

Average Drawdown

Average peak-to-trough decline

-88.38%

-10.71%

-77.67%

Ulcer Index

Depth and duration of drawdowns from previous peaks

55.06%

2.03%

+53.03%

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading charts...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of BioRestorative Therapies Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how BioRestorative Therapies Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for BRTX relative to other companies in the Biotechnology industry. Currently, BRTX has a P/S ratio of 12.7. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for BRTX in comparison with other companies in the Biotechnology industry. Currently, BRTX has a P/B value of 2.4. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
Portfolio Analyzer

Build a portfolio with BRTX

Add BioRestorative Therapies Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Analyzer with BRTX